Elite Pharmaceuticals, Inc. (ELTP) reported a significant increase in total revenues, reaching $84 million for the fiscal year ending March 31, 2025, an increase of 48.4% from $56.6 million the previous year. Operating income surged by 81.7% to $19.6 million, despite a pretax loss of $52,140 due to a non-cash derivative liability adjustment.
Despite a 15.7% decline in shares since the earnings report, the stock has rebounded by 7.2% over the past month. Elite Pharmaceuticals captured an estimated 8-10% market share in the lisdexamfetamine market shortly after its launch, contributing to its growth in the Attention Deficit Hyperactivity Disorder (ADHD) treatment category.
Operating cash flow stood at $7.5 million, an improvement from -3.2 million the prior year, with current liabilities decreased to $11.8 million from $13 million. CEO Nasrat Hakim highlighted the company’s strategy for continued growth and indicated that options, including mergers and acquisitions, are being considered for future expansion.
